Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib as second-line therapy for metastatic renal cell carcinoma
2008-001451-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of axitinib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started May 2008; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-001451-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001451-21.